SCI adv: a new therapeutic candidate antibody is expected to treat autoimmune diseases thoroughly

January 12, 2020 news / BIOON / -- multiple autoimmune Sexual diseases often involve the production of pathogenic immunoglobulin G (IgG) antibodies, which can attack cells and tissues and interact with antigens to form immune complexes Immune complexes are particularly dangerous because they can deposit in tissues and promote the further development of autoantibodies At present, they can only be removed or suppressed by invasive methods Photo source: cc0 public domain recently, a research report published in the international journal Science advanced, scientists from Brigham women's Hospital and other institutions found through human body research that they could block the new crystal fragment receptor (FcRn), or could potentially treat by removing IgG and its immune complex Autoimmune diseases In preclinical studies and phase 1 clinical trials, researchers have shown evidence that extending the role of FcRn to not only remove IgG antibodies from the circulatory system may show its potential in the treatment of autoimmune diseases According to Richard Blumberg, M.D., we predict that FcRn antibody therapy may become a part of new drug treatment for autoimmune diseases As these types of drugs enter the clinical practice, we need to pay more attention to their effects on IgG immune complex, which seems to be a problem that has not been paid attention to at present Previous studies have shown that blocking fcgn can reduce the level of IgG (the most common antibody in the blood) in human body IgG can play a key role in the body's resistance to infection by combining with viruses or bacteria, but it is also related to the occurrence of autoimmune diseases, such as lupus and pemphigus IgG can form immune complex with antigens, which will further promote the occurrence of autoimmune diseases, but the effect of blocking fcgn on immune complex has not been evaluated by researchers at present In this study, researcher Blumberg and his colleagues evaluated the effect of antibody synt001 (fcgn blocking monoclonal antibody) on IgG and IgG immune complex by studying mice, non-human primates and humans The results showed that synt001 can reduce the level of IgG and IgG immune complex in the process of circulation, while colleagues can inhibit the immune complex to activate the immune system The ability of this candidate drug in phase 1 clinical trials is better Finally, the researchers said that the related research results showed that sync001 could block fcgn or be expected to treat various types of autoimmune diseases and inflammatory diseases At the same time, it is also expected to serve as a potential therapeutic agent to help reverse the effects of pathogenic IgG and IgG immune complex Original sources: L J Blumberg, J E Humphries, S D Jones, et al Blocking FcRn in humans reducing circulating IgG levels and inhibits IgG immune complex – mediated immune responses, science advances 18 Dec 2019: Vol 5, No 12, eaax9586 doi: 10.1126/sciadv.aax9586